CONDUIT PHARMACEUTICALS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.94 USD | -1.01% |
|
-3.29% | -35.38% |
| 14/05 | Conduit Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 19/03 | Conduit Pharmaceuticals Inc. Appoints Joanne Holland as Chief Scientific Officer | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 33Cr 2.76TCr |
|---|---|---|---|---|---|
| Net income 2022 | -40L -33Cr | Net income 2023 | - 0 | EV / Sales 2022 | - |
| Net Debt 2022 | 20.1L 17Cr | Net cash position 2023 | 32.43L 27Cr | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-51
x | Employees | 7 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 13.35% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.01% | ||
| 1 week | -3.29% | ||
| Current month | -2.33% | ||
| 1 month | -4.85% | ||
| 3 months | -1.67% | ||
| 6 months | +151.11% | ||
| Current year | -35.38% |
1 week
2.80
3.15
1 month
2.803.50
Current year
2.255.29
1 year
0.9525.00
3 years
0.9525.00
5 years
0.9525.00
10 years
0.9525.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Tapolczay
CEO | Chief Executive Officer | 64 | 22/23/22 |
Adam Sragovicz
DFI | Director of Finance/CFO | 55 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Freda Lewis-Hall
CHM | Chairman | 69 | 22/23/22 |
| Director/Board Member | 50 | 22/23/22 | |
Faith Charles
BRD | Director/Board Member | 62 | 22/23/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/24/16 | 2.94 | -1.01% | 26,228 |
| 15/24/15 | 2.97 | +4.58% | 12,511 |
| 14/24/14 | 2.84 | -8.09% | 48,118 |
| 13/24/13 | 3.09 | +4.04% | 20,492 |
| 10/24/10 | 2.97 | -2.30% | 34,234 |
Delayed Quote Nasdaq, May 17, 2024 at 01:30 am IST
More quotes
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Companyâs licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimotoâs Thyroiditis. The Companyâs asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimotoâs Thyroiditis (HT and Gravesâ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimotoâs Thyroiditis and Gravesâ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
Calendar
14/11/2024
- Jefferies London Healthcare Conference
| 1st Jan change | Capi. | |
|---|---|---|
| -35.38% | 22Cr | |
| +32.09% | 5.08TCr | |
| +0.84% | 4.28TCr | |
| +48.94% | 4.2TCr | |
| -4.22% | 2.95TCr | |
| +10.95% | 2.61TCr | |
| -21.72% | 1.91TCr | |
| +8.31% | 1.31TCr | |
| +26.74% | 1.22TCr | |
| +23.39% | 1.21TCr |
- Stock Market
- Equities
- CDT Stock
